Gapping up
Select metals/mining stocks trading higher:
- ACH +4.3%, SLV +3.4%, AG +2.9%, EXK +2.8%, AU +2.5%, NG +2.2%, SA +2.2%, PAAS +2.2%, HL +2.2%, GOLD +2%, GLD +1.9%, GDX +1.9%, GFI +1.9%, HMY +1.9%, IAG +1.9%, KGC +1.7%, AA +1.7%, NEM +1.6%, AEM +1.4%, PAA +1.3%
Select oil/gas related names showing strength:
- CVX +6.5%, COP +5.1%, XLE +4.1%, XOM +3.2%, OXY +2%, DVN +0.9%, USO +0.6%
Other news:
- DVLT +22.8% (entered into a Master Purchase Order Agreement with AP Global)
- KZIA +22.6% (shares reopened after being halted on Friday)
- GHRS +16.2% (cleared to advance GH001 toward global Phase 3 in 2026)
- PBF +12.8% (provides update on Martinez refinery operations)
- ARBE +12.5% (combining Arbe's radar technology with NVIDIA (NVDA) accelerated computing)
- ATRA +8.6% (amends commercialization agreement with Pierre Fabre Medicament)
- NMRA +8.4% (reports results from NMRA-511 Phase 1b Signal-Seeking Study in Alzheimer's Disease Agitation; highlights 2026 pipeline strategy and anticipated upcoming milestones)
- POWW +7.2% (announces authorization of share repurchase program)
- CBUS +6.9% (Cibus Global and Interoc advance herbicide-tolerant rice commercialization in Latin America)
- QXO +5.9% (secures $1.2 bln preferred equity commitment to support acquisitions)
- NVA +5.3% (response to media article regarding Pakistani antimony concentrate)
- PLX +5.2% (provides several updates in letter to stockholders)
- CRWV +4.2% (disclosed amended credit agreement)
- RIOT +3.7% (names Jason Chung as CFO)
- FFAI +3.7% (enters into warrant termination agreements)
- CNCK +3.4% (files for $200 mln mixed securities shelf offering)
- ZURA +3.2% (entered into several agreements, issued shares)
- GYRE +2.8% (aligns with China CDE on conditional approval pathway for hydronidone)
- PLAB +2.1% (announcess that Chief Technology Officer Christopher Progler will be stepping away from his current role with the company as part of a planned leadership transition following more than 20 years of service)
- JBIO +2% (outlines key 2026 objectives and strategy to advance pipeline of potentially best-in-class monoclonal antibodies across multiple autoimmune diseases ahead of the 44th Annual J.P. Morgan Healthcare Conference)
- BBAI +1.9% (expects to eliminate approximately $125 million of debt through a combination of voluntary conversions by noteholders and the Company's redemption of any Notes that have not been converted through the Redemption Date)
- RANI +1.5% (entered into a securities purchase agreement; adopted amended and restated bylaws)
- CANG +1.4% (reports December 2025 bitcoin production update)
- HIMX +1.3% (confirms CPO collaboration and strategic partnership with FOCI remain unchanged)
- IMDX +1% (prepares for U.S. commercial launch of GraftAssuredx as clinical trial nears completion)